Synairgen PLC | Income Statement

Fiscal year is January-December. All values GBP Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
4,290.00
25.00
-
5,025.00
105
Cost of Goods Sold (COGS) incl. D&A
-
-
-
28.00
-
-
Gross Income
-
-
-
28.00
-
-
SG&A Expense
2,212.00
2,985.00
2,603.00
3,414.00
3,386.00
4,197
EBIT
2,274.00
1,258.00
2,609.00
3,442.00
1,615.00
4,132
Unusual Expense
4.00
164.00
-
-
-
-
Pretax Income
2,267.00
1,125.00
2,559.00
3,404.00
1,629.00
4,096
Income Tax
224.00
63.00
304.00
587.00
132.00
795
Consolidated Net Income
2,043.00
1,188.00
2,255.00
2,817.00
1,761.00
3,301
Net Income
2,043.00
1,188.00
2,255.00
2,817.00
1,761.00
3,301
Net Income After Extraordinaries
2,043.00
1,188.00
2,255.00
2,817.00
1,761.00
3,301
Net Income Available to Common
2,043.00
1,188.00
2,255.00
2,817.00
1,761.00
3,301
EPS (Basic)
0.03
0.01
0.02
0.03
0.02
0.03
Basic Shares Outstanding
75,186.70
83,899.00
91,317.00
91,351.40
91,363.00
95,263
EPS (Diluted)
0.03
0.01
0.02
0.03
0.02
0.03
Diluted Shares Outstanding
75,186.70
88,178.00
91,317.00
91,351.40
94,236.00
95,263
EBITDA
2,212.00
1,305.00
2,578.00
3,414.00
1,639.00
4,092
Non-Operating Interest Income
11.00
31.00
50.00
38.00
14.00
36

About Synairgen

View Profile
Address
Mailpoint 810, Level F, South Block
Southampton London & South East SO16 6YD
United Kingdom
Employees -
Website http://synairgen.com
Updated 07/08/2019
Synairgen Plc is a holding company, which engages in the provision of respiratory drug discovery and development. It focuses on severe asthma, chronic obstructive pulmonary disease, and severe viral infections. The company was founded by Donna E.